Nephrology Dialysis Transplantation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 14, 2024
ABSTRACT
Cognitive
decline
is
common
in
patients
with
acute
or
chronic
kidney
disease.
Several
areas
of
brain
function
can
be
affected,
including
short-
and
long-term
memory,
attention
inhibitory
control,
sleep,
mood,
eating
control
motor
function.
disease
shares
risk
factors
cognitive
dysfunction
people
without
disease,
such
as
diabetes,
high
blood
pressure,
sedentary
lifestyle
unhealthy
diet.
However,
additional
kidney-specific
may
contribute,
uremic
toxins,
electrolyte
imbalances,
inflammation,
acid–base
disorders
endocrine
dysregulation.
Traditional
interact
to
cause
damage
the
blood–brain
barrier,
induce
vascular
neurotoxicity
neuroinflammation.
Here,
we
discuss
recent
insights
into
pathomechanisms
from
animal
models
novel
avenues
for
prevention
therapy.
We
focus
on
a
several
that
influence
cognition:
barrier
disruption,
role
skeletal
muscle,
physical
activity
factor
irisin,
emerging
therapeutic
sodium-glucose
cotransporter
2
(SGLT2)
inhibitors
glucagon-like
peptide
1
(GLP-1)
receptor
agonists.
Taken
together,
these
studies
demonstrate
importance
providing
mechanistic
understanding
this
complex
condition
their
potential
explain
mechanisms
therapies.
The Journal of Prevention of Alzheimer s Disease,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100199 - 100199
Published: May 1, 2025
New-generation
antidiabetic
medications
may
have
therapeutic
potential
for
dementia,
beyond
their
glycemic
effects.
However,
information
from
observational
studies
exploring
the
association
between
new-generation
use
and
dementia
risk
is
limited.
To
examine
medication
risk.
Retrospective
cohort
study
using
electronic
health
records
of
a
large
non-profit
maintenance
organization.
84,798
dementia-free
individuals
aged
≥65y
with
type
2
diabetes.
Antidiabetic
exposure
was
based
on
purchased
prescriptions
used
as
time-varying
variable.
Exposure
periods
were
defined
in
which
either
dipeptidyl
peptidase-4
inhibitors
(DPP-4i),
sodium-glucose
cotransporter-2
(SGLT-2i),
or
glucagon-like
peptide-1
analogs
(GLP-1a)
combinations
used,
otherwise
unexposed.
Dementia
classification
International
Classification
Diseases,
Ninth
Revision
codes
antidementia
prescriptions.
Cox
regression
models
fitted
to
quantify
incident
dementia.
Models
adjusted
13
sources
confounding
inverse-probability
weighting.
Among
mean
diabetes
onset
age
66.4
±
7.5
years,
median
follow-up
8.7
years
(Q1-Q3:
5.4-12.8).
diagnosed
11,642
(13.7%)
individuals.
associated
reduced
(HR
=
0.69;
95%
CI,
0.66-0.73)
by
drug
classes
(DPP-4i,
HR
0.67
[95%
CI
0.63-0.71];
SGLT-2i,
0.63
0.56-0.70],
GLP-1a,
0.61
0.54-0.69].
The
results
this
large-scale
suggest
that
be
lower
older
adults
T2D.
Nephrology Dialysis Transplantation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 14, 2024
ABSTRACT
Cognitive
decline
is
common
in
patients
with
acute
or
chronic
kidney
disease.
Several
areas
of
brain
function
can
be
affected,
including
short-
and
long-term
memory,
attention
inhibitory
control,
sleep,
mood,
eating
control
motor
function.
disease
shares
risk
factors
cognitive
dysfunction
people
without
disease,
such
as
diabetes,
high
blood
pressure,
sedentary
lifestyle
unhealthy
diet.
However,
additional
kidney-specific
may
contribute,
uremic
toxins,
electrolyte
imbalances,
inflammation,
acid–base
disorders
endocrine
dysregulation.
Traditional
interact
to
cause
damage
the
blood–brain
barrier,
induce
vascular
neurotoxicity
neuroinflammation.
Here,
we
discuss
recent
insights
into
pathomechanisms
from
animal
models
novel
avenues
for
prevention
therapy.
We
focus
on
a
several
that
influence
cognition:
barrier
disruption,
role
skeletal
muscle,
physical
activity
factor
irisin,
emerging
therapeutic
sodium-glucose
cotransporter
2
(SGLT2)
inhibitors
glucagon-like
peptide
1
(GLP-1)
receptor
agonists.
Taken
together,
these
studies
demonstrate
importance
providing
mechanistic
understanding
this
complex
condition
their
potential
explain
mechanisms
therapies.
